Expert Outlook: PACS Group Through The Eyes Of 11 Analysts
In the preceding three months, 11 analysts have released ratings for PACS Group (NYSE:PACS), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 8 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 7 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $31.36, a high estimate of $35.00, and a low estimate of $27.00. Observing a 1.16% increase, the current average has risen from the previous average price target of $31.00.
Interpreting Analyst Ratings: A Closer Look
A clear picture of PACS Group's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tao Qiu | Macquarie | Announces | Outperform | $35.00 | - |
| David Macdonald | Truist Securities | Maintains | Buy | $32.00 | $32.00 |
| Ben Hendrix | RBC Capital | Raises | Outperform | $32.00 | $30.00 |
| Michael Wiederhorn | Oppenheimer | Raises | Outperform | $32.00 | $31.00 |
| Scott Fidel | Stephens & Co. | Maintains | Overweight | $31.00 | $31.00 |
| Scott Fidel | Stephens & Co. | Announces | Overweight | $31.00 | - |
| Calvin Sternick | JP Morgan | Announces | Overweight | $27.00 | - |
| Jason Cassorla | Citigroup | Announces | Buy | $32.00 | - |
| David Macdonald | Truist Securities | Announces | Buy | $32.00 | - |
| Ben Hendrix | RBC Capital | Announces | Outperform | $30.00 | - |
| Michael Wiederhorn | Oppenheimer | Announces | Outperform | $31.00 | - |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to PACS Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PACS Group compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for PACS Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into PACS Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on PACS Group analyst ratings.
About PACS Group
PACS Group Inc is a post-acute healthcare company primarily focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.
Financial Insights: PACS Group
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, PACS Group showcased positive performance, achieving a revenue growth rate of 31.94% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: PACS Group's net margin excels beyond industry benchmarks, reaching 5.26%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): PACS Group's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 43.85% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): PACS Group's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.33% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 23.61, caution is advised due to increased financial risk.
Understanding the Relevance of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.